Please login to the form below

Skyrizi

This page shows the latest Skyrizi news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

The positive Final Appraisal Document (FAD) means Skyrizi (risankizumab) is recommended for severe psoriasis treatment in adults who have failed conventional systemic therapies. ... The recommendation means that the NHS in England will make Skyrizi

Latest news

AbbVie to acquire Allergan for $63bn

AbbVie has had plenty of encouraging news from launches and late-stage pipeline read-outs in 2019, however, such as Skyrizi and upadacitinib, but these won't come close to making
AbbVie’s upadacitinib tops Humira again in arthritis trial

that with upadacitinib nearing approval decisions and Skyrizi already in launch mode, the future is looking bright for its immunology franchise. ... AbbVie has previously forecast Skyrizi's revenues to reach $5bn by 2023 – though analysts at Clarivate
Tremfya heads for filing in psoriatic arthritis

Cosentyx. While Stelara remains in a solid second place behind runaway leader Humira, Cosentyx, AbbVie’s Skyrizi, Eli Lilly’s Taltz and Pfizer's Xeljanz also already approved in psoriatic arthritis.
Lilly claims cluster headache first for CGRP drug Emgality

IL-23 inhibitor Skyrizi (risankizumab), and top-selling diabetes therapy Trulicity (dulaglutide) is also under pricing pressure.
Latecomer Lilly preps its IL-23 drug for Crohn’s disease

Stelara has since been joined by J&J’s follow-up IL-23 inhibitor Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie/Boehringer Ingelheim’s Skyrizi (risankizumab), which are all ... once again it is in a race with Skyrizi, which

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Developed by Boehringer Ingelheim and AbbVie, Skyrizi is a monoclonal antibody that inhibits the pro-inflammatory cytokine IL-23. ... Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director, Healthcare Communications: Salary TBC

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Account Director – UK Office: Excellent salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
The evolution of real-world studies: How industry and regulators are using real-world data...